Influenza vaccine for cardiovascular risk reduction
Related Experiment Video
Updated: May 4, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Patricia A Howard1, James W Kleoppel2
1Professor and Vice Chair.
Insights
Influenza vaccination may reduce cardiovascular death and coronary events in patients with existing cardiovascular disease. Pharmacists should prioritize vaccination for these high-risk individuals.
Area of Science:
- Public Health
- Cardiology
- Vaccinology
Background:
- Cardiovascular disease (CVD) is a major cause of illness and death globally.
- Patients with CVD face elevated risks of severe outcomes from influenza infections.
- Influenza poses a significant threat to cardiovascular health.
Purpose of the Study:
- To evaluate the potential benefits of influenza vaccination in individuals with cardiovascular disease.
- To highlight the importance of influenza vaccination for high-risk cardiovascular patients.
Main Methods:
- Review of current evidence on influenza vaccination and cardiovascular outcomes.
- Analysis of epidemiological data regarding influenza and CVD complications.
Main Results:
- Preliminary evidence indicates that influenza vaccination may lower the risk of cardiovascular death.
- The influenza vaccine might decrease the incidence of coronary events in susceptible populations.
- Further research is warranted to confirm these cardiovascular benefits.
Conclusions:
- Influenza vaccination is recommended for all eligible individuals, with particular emphasis on those with cardiovascular disease.
- Pharmacists play a crucial role in promoting influenza vaccination among high-risk cardiovascular patients.
- Proactive vaccination strategies can mitigate influenza-related risks in the cardiovascular patient population.
Abstract:
Cardiovascular disease is a leading cause of morbidity and mortality. Individuals with underlying cardiovascular disease are at high risk for adverse outcomes from influenza infections. Although additional studies are needed, current evidence suggests the influenza vaccine may reduce the risk of cardiovascular death and coronary events. In addition to their overall efforts to encourage influenza vaccination for all eligible persons, pharmacists should pay special attention to these high-risk individuals.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Influenza
Cardiovascular Drugs: Classification based on Therapeutic Indications
Rheumatic Heart Disease III: Medical Management
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Angina IV: Management

